Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 45 - Medicinal preparations containing active ingredients not provided for in groups
Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
11/2005
11/10/2005US20050250950 1,3-oxathiolane nucleoside analogues
11/10/2005US20050250854 Combination therapy using pentafluorobenzenesulfonamides and antineoplastic agents
11/10/2005US20050250852 For facilitating the delivery of active agents, such as insulin, to a target
11/10/2005US20050250851 Methods for treating neuropsychiatric disorders
11/10/2005US20050250843 synergistic antihypoxic mixture: acetylcholine esterase inhibitor (Donepezil and Tacrine) and neuroprotectant 1-[3-(2-(1-benzothiophen-5-yl)ethoxy)propyl]-3-azetidinol maleate; dysfunction of cerebral acetylcholine neurons in sequelae of cerebrovascular and senile dementia, Alzheimer's disease
11/10/2005US20050250834 11-(Aminoalkyl)isoindolo[2,1-a]indol-6-ones: 11-(2-Dimethylaminoethyl)-2-fluoroisoindolo[2,1-a]indol-6-one; psychological disorders, drug abuse, sleep disorders, Alzheimer's, Parkinson's and Huntington's disease, Irritable bowel syndrome, chemotherapy induced emesis, spinal trauma and/or head injury
11/10/2005US20050250832 For increasing blood-brain barrier permeability
11/10/2005US20050250803 Combination of dopamine agonists and monoamine reuptake inhibitors
11/10/2005US20050250801 Method of treating cancer with azaspirane compositions
11/10/2005US20050250758 Nitrosated and nitrosylated H2 receptor antagonist compounds, compositions and methods of use
11/10/2005US20050250757 Use of targeted oxidative therapeutic formulation in treatment of cancer
11/10/2005US20050250756 Use of targeted oxidative therapeutic formulation in treatment of age-related macular degeneration
11/10/2005US20050250755 administering to the patient an effective amount of a pharmaceutical formulation comprising:reaction products resulting from oxidation of menthol or an alkene such as geraniol by an oxygen-containing oxidizing agent; a penetrating solvent dimethylsulfoxide; a chelated dye; and an aromatic redox compound
11/10/2005US20050250734 Compositions, kits, and methods for the treatment of conditions associated with elevated cholesterol levels
11/10/2005US20050250730 Combination of an adenosine A2A-receptor agonist and tiotropium or a derivative thereof for treating obstructive airways and other inflammatory diseases
11/10/2005US20050250727 Use of immunomodulating agents
11/10/2005US20050250726 Immunostimulatory nucleic acid for treatment of non-allergic inflammatory diseases
11/10/2005US20050250720 Novel compound
11/10/2005US20050250716 Immunostimulatory oligodeoxynucleotides
11/10/2005US20050250709 Anti-neoplastic agents, combination therapies and related methods
11/10/2005US20050250707 HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis
11/10/2005US20050250701 Method of treating the syndrome of coronary heart disease risk factors in humans
11/10/2005US20050250672 Using antihyperplastic agent; diffusion through capillaries; imaging veins, arteries; side effect reduction; antitumor agents
11/10/2005US20050250167 Purified pkb ser 473 kinase and uses thereof
11/10/2005US20050250160 Methods and compositions using stearoyl-CoA desaturase to identify triglyceride reducing therapeutic agents
11/10/2005US20050249821 Nutritional supplement for treatment of ocular diseases
11/10/2005US20050249820 Nutritional supplement for the treatment and prevention of macular degeneration
11/10/2005US20050249818 Polycationic antimicrobial therapeutic
11/10/2005US20050249811 Pharmaceutical compositions for the coordinated delivery of NSAIDs
11/10/2005US20050249809 Novel pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
11/10/2005US20050249806 Combination of proton pump inhibitor, buffering agent, and nonsteroidal anti-inflammatory drug
11/10/2005US20050249797 Self forming, thermodynamically stable liposomes and their applications
11/10/2005US20050249795 Gemcitabine compositions for better drug delivery
11/10/2005US20050249793 Athletic patch
11/10/2005US20050249783 Method of improving absorption of vitamin e by a pet animal
11/10/2005US20050249731 Methods of implating mesenchymal stem cells for tissue repair and formation
11/10/2005US20050249717 Use of hyaluronidase for preventing and treating cardio vascular diseases
11/10/2005US20050249712 Methods for use of TSLP and agonists and antagonists thereof
11/10/2005US20050249710 biodegradable drug delivery system containing an immunosuppressive agent and a bioerodible polymer comprising hydroxyaliphatic carboxylic acids, and polysaccharides
11/10/2005US20050249708 Cerebral Intraventricular Transplantation as Method of Treating Amyotrophic Lateral Sclerosis (ALS)
11/10/2005US20050249706 Using transgenic and attenuated salmonella comprising tumor modulatory proteins and pharmceutical conjugate to treat cell proliferative disorders; targeted tissue therapy
11/10/2005US20050249704 Method of treating autoimmune diseases with interferon-beta and il-2r antagonist
11/10/2005US20050249700 Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
11/10/2005US20050249691 Cosmetic or dermatological preparation comprising a nutrient medium phase
11/10/2005US20050249675 Mucin synthesis inhibitors
11/10/2005US20050249664 Methods for measuring rates of reserve cholesterol transport in vivo, as an index of anti-atherogenesis
11/10/2005US20050249663 Coadministration of transport protein with conjugated cobalamin to deliver agents
11/10/2005US20050247312 Medicament dispenser
11/10/2005DE102004019540A1 Composition, useful for treatment of e.g. inflammatory and obstructive respiratory complaint, sinus rhythm in heart in atrioventricular block and circulatory shock, comprises 6-hydroxy-4H-benzo1,4oxazin-3-one derivatives and other actives
11/10/2005DE10112926B4 Verwendung von Aminooxyacetat zur Tumorbehandlung Use of aminooxyacetate for tumor treatment
11/10/2005CA2568436A1 Combination therapy comprising an adenosine a1 receptor antagonist and an aldosterone inhibitor
11/10/2005CA2565832A1 Preparation for the treatment cancer
11/10/2005CA2565628A1 The combination of prostaglandin e2 receptor antagonist and renin-angiotensin system inhibitor for treating renal diseases
11/10/2005CA2564877A1 Formulation comprising histone deacetylase inhibitors
11/10/2005CA2564258A1 Histamine-3 receptor antagonists
11/10/2005CA2563569A1 Combinations comprising a s1p receptor agonist and a jak3 kinase inhibitor
11/10/2005CA2563222A1 Novel imidazoles
11/10/2005CA2562585A1 Dpi formulation containing sulfoalkyl ether cyclodextrin
11/10/2005CA2553721A1 Inhibition of biogenic sulfide production via biocide and metabolic inhibitor combination
11/09/2005EP1593394A2 Ionically crosslinked carboxyl-containing polysaccharides for adhesion prevention
11/09/2005EP1593387A1 Compositions for the treatment of impaired interpersonal and behavioral disorders
11/09/2005EP1593386A1 Use of galectin-2
11/09/2005EP1593382A1 Use of probiotic lactic bacteria for balancing the skin's immune system
11/09/2005EP1592780A2 Dyrks as modifiers of the apc and axin pathways and methods of use
11/09/2005EP1592449A2 Sensitizing cells for apoptosis by selectively blocking cytokines
11/09/2005EP1592447A1 Devices and compositions containing boron and silicon for use in neutron capture therapy
11/09/2005EP1592445A2 Method of inhibiting infection by hcv, other flaviviridae viruses, and any other virus that complexes to low density lipoprotein or to very low density lipoprotein in blood preventing viral entry into a cell
11/09/2005EP1592435A1 Ophthalmic formulation for the prevention and treatment of ocular conditions
11/09/2005EP1592432A2 Modified polysaccharides combination with anti-cancer drugs for enhanced treatment of cancer
11/09/2005EP1592429A1 Method for inhibition of necrosis induced by neurotrophin
11/09/2005EP1592427A1 Multivitamin regimen for renal patients
11/09/2005EP1592424A1 Cabergoline for the prophylactic treatment of migraine
11/09/2005EP1592422A2 New pharmaceutical compositions based on anticholinergics and inhibitors of tnf alpha synthesis or action
11/09/2005EP1592420A1 Clindamycin phosphate foam
11/09/2005EP1592388A2 Methods for diagnosis anf monitoring of neurological disease by detection of an encephalotoxin
11/09/2005EP1592387A2 Composition for and treatment of demyelinating diseases and paralysis by administration of remyelinating agents
11/09/2005EP1592386A2 Composition for and treatment of demyelinating diseases and paralysis by administration of remyelinating agents
11/09/2005EP1405083B1 Natural ligand of gpcr chemr23 and uses thereof
11/09/2005EP1368025B1 Compositions useful for the treatment of pathologies responding to the activation of ppar-gamma receptor
11/09/2005EP1309349B1 Pharmaceutical composition and method for the treatment of retroviral infections
11/09/2005EP1307196A4 Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation
11/09/2005EP1255541B1 Aromatic guanylhydrazone for the treatment of resistant viral infections
11/09/2005EP1218376B1 Tyrosine kinase inhibitors
11/09/2005EP1216223B1 Novel dicarboxylic acid derivatives with pharmaceutical properties
11/09/2005EP1212421B1 Gas1 polypeptides
11/09/2005EP1212069B1 Improved topical compositions containing extracellular products of probiotic bacteria and uses thereof
11/09/2005EP1165576B1 Process for preparing amine platinum complexes
11/09/2005EP1130964B1 Therapeutic anti-fungal nail preparation
11/09/2005EP1087747B1 Foaming composition for hair care
11/09/2005EP1066041B1 THE USE OF17-ALPHA-ESTRADIOL DERIVATIVES FOR TREATING SIDE-EFFECTS DURING AND/OR AFTER GnRHa THERAPY
11/09/2005EP1042275B1 Anticonvulsant and central nervous system-active bis(fluorophenyl)alkylamides
11/09/2005EP0971745B1 Gel delivery vehicles for anticellular proliferative agents
11/09/2005EP0943008B1 Metal mediated serine protease inhibitors
11/09/2005EP0844874B1 METHODS AND COMPOSITIONS USEFUL FOR INHIBITION OF ALPHA v BETA 5 MEDIATED ANGIOGENESIS
11/09/2005EP0792162B1 Use of antibodies to block the effects of gram-positive bacteria and mycobacteria
11/09/2005EP0772455B1 Intracellular expression of carboxypeptidase g2 in enzyme prodrug therapy
11/09/2005CN1695059A Method of diagnosing colon and gastric cancers
11/09/2005CN1694900A EE3-protein family and corresponding DNA sequences
11/09/2005CN1694868A Phenyl-indole compounds for modulating ige and inhibiting cellular proliferation
11/09/2005CN1694867A Crystal for oral solid drug and oral solid drug for dysuria treatment containing the same
1 ... 443 444 445 446 447 448 449 450 451 452 453 454 455 456 457 458 459 460 461 462 463 ... 1151